Company Overview of BiPar Sciences, Inc.
BiPar Sciences, Inc., a biopharmaceutical company, offers development and commercialization tumor-selective drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded in 2002 and is headquartered in Brisbane, California. As of April 27, 2009, BiPar Sciences, Inc. operates as a subsidiary of Sanofi.
1000 Marina Boulevard
Brisbane, CA 94005
Founded in 2002
Key Executives for BiPar Sciences, Inc.
Similar Private Companies By Industry
|Catabasis Pharmaceuticals, Inc.||United States|
|Exponential Biotherapies, Inc.||United States|
|Naturex, Inc.||United States|
|Alfama, Inc.||United States|
|Foresight Biotherapeutics, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact BiPar Sciences, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.